Clinical Trials Logo

Chronic Lymphocytic Leukemia (CLL) clinical trials

View clinical trials related to Chronic Lymphocytic Leukemia (CLL).

Filter by:

NCT ID: NCT01279252 Completed - Clinical trials for Chronic Lymphocytic Leukaemia (CLL)

CLL Empirical Antibiotic Regimen

CLEAR
Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether patients with previously untreated, early stage CLL respond to empirical broad spectrum antibiotics and therefore test the hypothesis that occult bacterial infections are involved in the induction and maintenance of CLL.

NCT ID: NCT01251575 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Start date: December 1, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with sirolimus, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.

NCT ID: NCT01188681 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the first part of the study is to determine a safe dose of TRU-016 that can be used in combination with bendamustine in patients with relapsed CLL. The objectives of the second part of the study are to compare the safety and efficacy of TRU-016 in combination with bendamustine to bendamustine alone in patients with relapsed CLL.

NCT ID: NCT00919321 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL

KLL2
Start date: June 2009
Phase: Phase 4
Study type: Interventional

Patients with chronic lymphocytic leukemia (CLL)have had very poor humoral responses to pneumococcal polysaccharide vaccine (PPV). The vaccine in which pneumococcal polysaccharide antigens are conjugated to protein (PCV) have been immunogenic in CLL patients in our previous studies. The purpose of this study is to evaluate the duration of these vaccine-induced antibodies and the function of memory cells by giving a one dose of PPV-vaccine after several years of PCV-vaccination.

NCT ID: NCT00889798 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Tumor Registry of Lymphatic Neoplasia

TLN-Registry
Start date: April 2009
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

NCT ID: NCT00710528 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.

NCT ID: NCT00694590 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine if plerixafor can make CLL/SLL (Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma) cells more sensitive to being killed by rituximab, an anti-cancer drug that is commonly used in treating CLL and SLL. In this study, plerixafor will be added to standard treatment with rituximab. Subjects will be monitored to see how well they tolerate the use of these drugs together and how well they work to treat the leukemia. The primary objective is to determine the maximum tolerated dose (MTD) of plerixafor when combined with rituximab as treatment for previously treated patients with CLL or SLL.

NCT ID: NCT00640523 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To evaluate the effectiveness and safety of forodesine in CLL patients

NCT ID: NCT00614042 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.

NCT ID: NCT00458679 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

PRIMAL
Start date: December 2006
Phase: Phase 1
Study type: Interventional

We would like patients to be in a research study to determine the safety and effectiveness of special cells that may make their own immune system fight their cancer. To do this, we will put a special gene into cancer cells that have been taken from the patients body. This will be done in the laboratory. This gene will make the cells produce interleukin 2 (IL-2), which is a natural substance that may help their immune system kill cancer cells. Additionally, we will stimulate the cancer cells with normal embryonic fibroblasts (cells that develop into normal connective tissues in the body) so that they will make another natural protein called CD40 ligand (CD40L). Studies of cancers in animals suggest IL-2 performs better when mixed with CD40L. Some of these cells will then be put back into the patients body with the goal that they will act like a vaccine and stimulate their immune system to attack the CLL cells. Studies of cancers in animals and in cancer cells that are grown in laboratories suggest that combining substances like IL-2 and CD40L with cancer cells help the body recognize and kill cancer cells. We have already conducted a study similar to this in patients with CLL. In that study, the subjects received about three months of injections (shots). In those subjects we saw some changes in the subject's immune system that might indicate that the modified cells were helping their immune system fight the cancer. However, in most of the subjects this change in the immune system went away after the injections were stopped. In this study we want to see if we can make the change in the immune system last longer by giving more injections over a longer period of time. We hope that this might produce a better response directed at the CLL cells. We will also be looking at the effect on cells called cancer stem cells which grow into the CLL cells we see in the blood. Specifically, this study will allow subjects to receive the injections for up to one year.